



Intracerebral Hemorrhage: Advances in Preclinical Studies

Guest Editor:

Dr. Sangeetha Sukumari-Ramesh

Department of Pharmacology
and Toxicology, Medical College
of Georgia, Augusta University,
Augusta, GA 30912, USA

Deadline for manuscript
submissions:

closed (15 June 2022)

Message from the Guest Editor

Intracerebral hemorrhage (ICH) is a major public health problem and severe subtype of stroke characterized by cerebral bleeding. In comparison to other stroke subtypes, ICH is associated with the highest mortality and morbidity rates. Additionally, the incidence of ICH is expected to increase due to aging and the increasing use of anticoagulants. To date, there is no effective treatment for ICH, making it the deadliest subtype of stroke.

ICH results in severe brain injury, which is categorized into primary and secondary brain damage. The primary brain damage is mainly attributed to the mass effect of the hematoma, whereas the mechanisms of the secondary brain damage include, but are not limited to, neuroinflammation, oxidative stress, apoptosis, and excitotoxicity. The secondary brain injury, which persists for a longer period, contributes to long-term neurological deficits and is considered a viable target for therapeutic intervention. However, given the complex pathophysiology of ICH, further elucidation of the brain injury mechanisms is imperative for the identification of novel molecular targets for therapeutic intervention.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
[X@Biomol_MDPI](https://twitter.com/Biomol_MDPI)